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Abstract
Incidence and outcome of microbiologically documented bacterial/viral infections and invasive fungal disease (IFD) in children
and adults after hematopoietic cell transplantation (HCT) were compared in 650 children and 3200 adults in multicenter cross-
sectional nationwide study. Infections were diagnosed in 60.8% children and 35.0% adults, including respectively 69.1% and
63.5% allo-HCT, and 33.1% and 20.8% auto-HCT patients. The incidence of bacterial infections was higher in children (36.0%
vs 27.6%; p < 0.0001). Infections with Gram-negative bacteria were more frequent than Gram-positives in adults (64.6% vs
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44.8%; p < 0.0001). Outcome of bacterial infections was better in children (95.5% vs 91.4%; p = 0.0011). The IFD incidence
(25.3% vs 6.3%; p < 0.0001) and outcome (88.0% vs 74.9%; p < 0.0001) were higher in children. The incidence of viral
infections was higher in children after allo-HCT (56.3% vs 29.3%; p < 0.0001), and auto-HCT (6.6% vs 0.8%; p < 0.0001).
Outcome of viral infections was better in children (98.6% vs 92.3%; p = 0.0096). Infection-related mortality was 7.8% in children
and 18.4% in adults (p < 0.0001). No child after auto-HCT died of infection. Adult age, mismatched transplants, acute leukemia,
chronic GVHD, CMVreactivation, infection with Gram-negatives, and duration of infection > 21 days were risk factors for death
from infection. In conclusion, pediatric patients have 2.9-fold higher incidence and 2.5-fold better outcome of infections than
adults after HCT.
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Introduction
Infections are a significant cause of morbidity, mortality, and
resource utilization after hematopoietic cell transplantation
(HCT) in children and adults. Bacterial infections both after
allo- and auto-HCT are known to be associated with high
mortality and have become a public health problem of major
concern worldwide due to antibiotic resistance. Invasive fun-
gal disease (IFD) remains an important cause of morbidity and
mortality after allo-HCT. The incidence of IFD has been re-
ported at 9% after allo-HCT with mortality up to 50% of
patients, especially after alternative donor transplantations
[1–3]. Most studies have reported a high rate of viral infection
after allo-HCT but not auto-HCT. High viral infection risk
after allo-HCT is likely related to the delayed immune recon-
stitution after transplantation [4]. Recent EBMT (European
Society for Blood and Marrow Transplantation) analysis
showed that infections are responsible for 21.6% of deaths
after allo-HCT and 11.0% after auto-HCT in all age groups
together; however, the risk, types, and outcome of infections
varied between age groups [5].
Infections occur in up to 82% of children [6–8] and adults
[9–11] after HCT; however, large multicenter studies on inci-
dence and outcome of bacterial, fungal, and viral infections
are lacking. So far also no direct simultaneous comparison
was made between children and adults.
In this study, we compared the incidence, type, and out-
come of infections in pediatric and adult HCT centers in
Poland in multicenter cross-sectional nationwide study. We
analyzed also risk factors for the incidence and outcome of
infections in 650 children and 3200 adults who received HCT.
Patients and methods
Design of the study All consecutive patients transplanted be-
tween 1.01.2012 and 31.12.2015 in 5/5 pediatric, and in 11/
13, adult HCT Polish centers were included in the
retrospective study. Bacterial, fungal, and viral infections were
reported biannually by each center and data were analyzed
centrally.
Bacterial infections Among bacterial infections, only microbi-
ologically documented (MDI) episodes were considered.
Colonizations were not included into this analysis. MDI were
diagnosed as bloodstream, gut, urinary tract, respiratory tract
(broncho-alveolar lavage), and skin and soft tissue infections.
Bacteria were analyzed with attention to resistance profile, such
as ESBL (extended-spectrum β-lactamases: bacteria producing
extended-spectrum β-lactamases), AmpC (AmpC β-
lactamases: bacteria producing chromosomal cephalosporinase
AmpC type), KPC (Klebsiella pneumoniae carbapenemase,
Enterobacteriaceae producing carbapenemase KPC type)
[12], MRSA/MRSE (methicillin-resistant Staphylococcus
aureus or epidermidis), or VRE (vancomycin-resistant entero-
cocci). Multidrug resistant (MDR) bacteria denote resistance to
at least two antibiotics used in empiric therapy or resistance to
at least three of antibiotic classes [13, 14].
Fungal infections The diagnosis of IFD was made according
to EORTC/MSG criteria as proven, probable, or possible
[15–17]. Patients were screened with galactomannan test
mainly during neutropenia or on the basis of clinically driven
indications. Diagnostics for Pneumocystis jiroveci pneumonia
(PjP) was performed in case of clinical indications.
Viral infections Viral infections were classified as episodic
(diagnosed on the basis of clinical picture, and supplemented
with appropriate tests) or latent (diagnosed at molecular level).
The following viruses were detected by PCR analysis: adeno-
virus (ADV), polyoma BKV, cytomegalovirus (CMV),
Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6),
and community-acquired respiratory viruses (CARV) includ-
ing influenza.
Supportive therapy Uniform, standard anti-infective prophy-
laxis has been applied for patients undergoing HCT.
2198 Ann Hematol (2019) 98:2197–2211
Prophylactic, empirical, preemptive, or targeted anti-
infectious therapy was performed with various antibacterial,
antiviral, and antifungal agents according to commonly ac-
cepted strategies [13, 14, 18–21].
Prophylaxis of infections Environmental prophylaxis was ap-
plied in all centers according to commonly accepted policy
[22]. In children, antibacterial prophylaxis consisted of oral
penicillin or second-generation cephalosporin (from day −
10, until neutrophil count > 1 × 109/L or end of immunosup-
pressive treatment) and oral gentamicin used from the begin-
ning of conditioning until hematological recovery. Children
received antifungal prophylaxis with fluconazole; from
2014, posaconazole was used in case of graft versus host
disease (GVHD) or in secondary prophylaxis. In children un-
der age of 12 years, the drug was used off-label [17] and
administered according to body weight, as shown by Welzen
et al [23]. In adults during neutropenia, fluoroquinolones were
used for antibacterial prophylaxis and fluconazole in antifun-
gal prophylaxis together with regular screening of serum
galactomannan and computed tomography (HRCT/CT) in
case of suspected IFD. Both in children and adults, acyclovir
was used in prophylaxis of HSV/VZV infection until 1 year
post-transplant.Weekly screening for DNA-emia and preemp-
tive treatment were performed for CMVand EBVreactivation.
Prevention of PjP included cotrimoxazole after hematopoietic
recovery until the end of immunosuppressive treatment.
Commercial immunoglobulin preparations were given in case
of decreased immunoglobulin concentration during the first
month and then monthly until B cell function recovery. Most
of children receiving myeloablative conditioning (MAC) were
commenced on gut rest from the first 5 days after HCT and
received total parenteral nutrition (TPN) until hematopoietic
recovery.
Types of transplants Transplants were divided as autologous
and allogeneic from matched sibling donors (MSD) or unre-
lated donors: matched (MUD) or mismatched (MMUD).Most
patients who underwent MUD/MMUD-HCT received anti-
thymocyte globulin (ATG) [24].
Statistical analysis For analysis of incidence, infectious event
was defined as the diagnosis of a first specific infectious dis-
order. Categorical variables were compared with the chi-
square test, non-categorical variables were compared with
the Mann-Whitney U test. Odds ratio (OR) and confidence
intervals (95%CI) were calculated for the difference in occur-
rence of infections in patients. Cumulative 2-year incidences
of bacterial, fungal, or viral infections were calculated using
competing risk analysis [25], starting from the day of trans-
plant to the day of the first infection. Death was considered as
the competing event. Outcome of infection was regarded as
positive in case of survival from infection or negative in case
of death from infection. Infection-related mortality (IRM) was
defined as any death that occurred in the presence of infection,
starting from the day of diagnosis of infection. Death from
infection was diagnosed as of bacterial, fungal, or viral cause;
however, in many cases of IRM, patients suffered from mul-
tiple infections, and clinically the most symptomatic infection
was regarded as the primary cause of death. In case of relapse
and progression of malignancy, this was regarded as the primary
cause of death, regardless of concomitant infection. The Kaplan-
Meier method was used to determine IRM, counting from the
day of diagnosis of infection. The relationship between the bi-
nary outcome, infection incidence, or death from infection, and
other variables, regarded as risk factors, were analyzed using
multivariate logistic regression: hazard risk (HR) and 95%CI
were calculated for each factor. All reported p values are two-
sided; p < 0.05 was considered as statistically significant.
Results
Overall characteristics of infections
A total number of 395/650 (60.8%) children and 1120/3200
(35.0%) adults (OR = 2.9, 95%CI = 2.0–3.6; p < 0.0001) were
diagnosed for bacterial/viral MDI or IFD, including 345/499
(69.1%) and 676/1070 (63.5%) patients, respectively, after
allo-HCT, while 50/151 (33.1%) and 444/2130 (20.8%) re-
spectively, patients after auto-HCT. Patient characteristics
and number of infections are shown in Table 1.
Total number of infectious episodes was 3180, including
1399 in children (2.15 per patient) and 1781 in adults (0.56 per
patient) (p < 0.0001). Also respective numbers of infections
per patient were higher in children for bacterial (0.88 vs
0.37; p < 0.0001), fungal (0.38 vs 0.06; p < 0.0001), and viral
(0.89 vs 0.13; p < 0.0001) episodes.
Bacterial infections
Incidence The 2-year incidence of bacterial infections was
36.0% for children and 27.6% for adult patients
(p < 0.0001), including allo-HCTs (36.9% vs 41.1%, ns),
and auto-HCTs (32.9% vs 20.8%; p < 0.0001) (Fig. 1a–c).
These numbers were however comparable for specific prima-
ry diseases including acute lymphoblastic leukemia (ALL),
acute myeloblastic leukemia/myelodysplastic syndrome
(AML/MDS), non-Hodgkin lymphoma/Hodgkin lymphoma
(NHL/HD), and severe aplastic anemia (SAA). Only 12.9%
adults with multiple myeloma (MM) after auto-HCT had bac-
terial infections (Table 2).
Infections with Gram-negative bacteria were more frequent
than Gram-positive in adults (64.6%), but not in children
(44.8%). The difference was highly significant (p < 0.0001;
OR = 2.3, 95%CI = 1.8–2.7). The frequency of G-negative
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bacteria with MDR phenotype was 67.8% (158/233) in children
and 47.9% (404/843) in adults (OR = 2.3; 95%CI = 1.7–3.1,
p < 0.0001). The frequency of G-positive bacteria with MDR
phenotype was 43.6% (125/287) in children and 40.1% (185/
461) in adults (OR= 1.1; ns). Detailed etiology of G-negative
and G-positive infections is presented in Tables 3 and 4.
Timing Median time from the day of HCT to bacterial infec-
tion was 0.20 months (range − 0.2–20.6) in children and
0.23 months (range − 0.3–36.9) in adults. Median time of
therapy of bacterial infection was 14 days (range 1–196; quar-
tiles 10–21) in children and 9 days (range 1–36; quartiles 8–
14) in adults (p < 0.0001).
Table 1 Characteristics of
patients Characteristics Children Adults p
All patients
Total 650 3200
Allo-HCT 499 (76.8%) 1070 (33.4%) < 0.0001
Auto-HCT 151 (23.2%) 2130 (66.6%) < 0.0001
Acute lymphoblastic leukemia (ALL) 153 (23.2%) 211 (6.6%) < 0.0001
Acute myeloid leukemia (AML) 98 (15.1%) 472 (14.8%) 0.8306
Myelodysplastic syndromes (MDS) 32 (4.9%) 79 (2.5%) 0.0006
Non-Hodgkin lymphoma (NHL)/Hodgkin
lymphoma (HD)
50 (7.7%) 803 (25.1%) < 0.0001
Severe aplastic anemia (SAA)/bone marrow
failure (BMF)
75 (11.5%) 58 (1.8%) < 0.0001
Other
Primary immunodeficiencies (PID) 75 (11.5%)
Neuroblastoma (NBL) 49 (7.5%)
Ewing sarcoma (ES) 13 (2.0%)
Multiple myeloma (MM) 1308 (40.9%)
Chronic myeloid leukemia
(CML)/myeloproliferative neoplasms (MPN)
119 (3.8%)
Other 43 (6.6%) 122 (3.8%)
Patients with infections
Total number of patients with infections Children (n = 395) Adults (n = 1120)
Sex: male/female 230 (58.2%)/165
(41.8%)
634 (56.6%)/486
(43.4%)
0.5758
Age at HCT: median (range) [years] 7.2 (0.1–18.0) 50.1 (18.0–77.8) < 0.0001
Donor type < 0.0001
Sibling 97 (24.6) 224 (20.0)
Mismatched related 4 (1.0) 2 (0.2)
Unrelated 244 (61.7) 450 (40.2)
Autologous 50 (12.7) 444 (39.6)
Stem cell source < 0.0001
Peripheral blood (PB) 243 (61.5) 1058 (94.5)
Bone marrow (BM) 149 (37.7) 62 (5.5)
Cord blood (CB) 3 (0.8) 0 (0.0)
TBI given: yes/no 64 (16.2%)/331
(83.8%)
170 (15.2%)/950
(84.8%)
0.6282
Reduced intensity/standard conditioning 71 (18.0%)/324
(82.0%)
157 (14.0%)/963
(86.0%)
0.0585
Acute GVHD: yes/no (including auto-HCT) 92 (23.3%)/303
(76.7%)
166 (14.8%)/954
(85.2%)
0.0001
Neutrophil engraftment by day + 100: yes/no 378 (95.7%)/17
(4.3%)
1067 (95.3%)/53
(4.7%)
0.7273
Time to neutrophil engraftment: median (range) [days] 14.0 (8–51) 16.0 (6–60) < 0.0001
Follow-up after HCT: median (range) [months] 21 (0–48) 19 (0–41) 0.6924
Legend: HCT, hematopoietic stem cell transplantation; TBI, total body irradiation; GVHD, graft versus host
disease
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Risk factors In multivariate logistic analysis (Table 5), the risk of
infections was higher after allo-HCT than auto-HCT (HR= 1.8;
p < 0.001). In allo-HCT patients, the risk was higher in children
(HR= 2.1; p < 0.001), in acute leukemia (HR = 1.6; p < 0.001),
MUD vs MSD-HCT (HR= 1.6; p < 0.001), MMUD vs MSD-
HCT (HR= 2.0; p < 0.001), MAC (myeloablative conditioning)
vs RIC (reduced-intensity conditioning) (HR = 1.3; p < 0.001),
late (> 21 days) hematological recovery (HR = 3.3; p < 0.001),
acute GVHD before infection (HR = 1.7; p < 0.001), and chron-
ic GVHD before infection (HR = 1.4; p = 0.014). In auto-HCT
Fig. 1 Incidence of infections. a Total, b allo-, and c auto-HCT bacterial infections. d Total, e allo-, and f auto-HCT fungal infections. g Proven, h
probable, and i possible IFD. j Total viral infections. k, l CMV, BKV, EBV, and ADV infections in children and adult
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patients, the risk was higher in children (HR = 1.7; p < 0.001),
and in patients with late (> 21 days) hematological recovery
(HR = 2.8; p < 0.001). In patients with multiple myeloma
(MM), the risk was lower in comparison to all other patients
(HR= 0.7; p = 0.005).
Outcome Overall outcome of bacterial infections was positive
in 95.5% of infections in children and in 91.4% in adults
(OR = 3.2; 95%CI = 1.6–6.5; p = 0.0011). The outcome of in-
fections was better in children both after allo- and auto-HCT
(Fig. 2a–c).
Table 2 Frequency of infections
Parameter Children Adults OR p
Bacterial infections
Total 36.0% (234/650) 27.6% (882/3200) 1.5 (1.2–1.8) < 0.0001
Allo-HCT 36.9% (184/499) 41.1% (440/1070) 0.8 (0.7–1.04) 0.1093
Auto-HCT 32.9% (50/151) 20.8% (444/2135) 1.9 (1.3–3.7) 0.0004
ALL 45.1% (69/153) 42.6% (90/211) 1.1 (0.7–1.6) 0.6426
AML 38.8% (38/98) 38.8% (183/472) 1.0 (0.6–1.5) 0.9752
MDS 34.8% (11/32) 38.0% (30/79) 0.9 (0.4–2.0) 0.7218
NHL/HD 28.0% (14/50) 19.7% (158/803) 1.6 (0.8–3.0) 0.1546
SAA/BMF 25.3% (19/75) 19.0% (11/58) 1.4 (0.6–3.3) 0.3835
Other
PID 37.3% (28/75) – ND ND
NBL 44.9% (44/98) – ND ND
ES 30.8% (8/26) – ND ND
MM – 12.9% (169/1308) ND ND
Fungal infections
Total 25.3% (163/650) 6.3% (183/3200) 5.5 (4.3–6.9) < 0.0001
Possible 16.9% (98/650) 2.3% (91/3200) 6.1 (4.5–8.1) < 0.0001
Probable 5.7% (42/650) 2.1% (49/3200) 4.4 (2.9–6.8) < 0.0001
Proven 2.7% (31/650) 1.6% (43/3200) 3.7 (2.3–5.9) < 0.0001
Allo-HCT 28.3% (142/499) 14.0% (132/1070) 2.8 (2.1–3.7) < 0.0001
Auto-HCT 14.7% (21/151) 2.5% (51/2135) 6.6 (3.8–11.3) < 0.0001
ALL 29.4% (45/153) 11.3% (24/211) 3.2 (1.8–5.6) < 0.0001
AML/MDS 41.2% (47/114) 13.2% (73/551) 4.6 (2.9–7.2) < 0.0001
Viral infections
Auto-HCT 6.6% (10/151) 0.8% (17/2135) 8.8 (4.0–19.6) < 0.0001
Allo-HCT 56.3% (281/499) 29.3% (314/1070) 3.1 (2.5–3.8) < 0.0001
Multiple viral infections 34.5% (97/281) 27.1% (85/314) 1.4 (1.0–2.0) 0.0498
Adenovirus (ADV) 7.4% (37/499) 2.9% (31/1070) 3.5 (2.0–6.0) < 0.0001
Polyoma BKV (BKV) 21.0% (104/499) 5.2% (63/1070) 5.2 (3.7–7.5) < 0.0001
Cytomegalovirus (CMV) 28.9% (144/499) 24.7% (264/1070) 1.7 (1.3–2.1) < 0.0001
Epstein-Barr virus (EBV) 19.4% (97/499) 1.9% (20/1070) 15.7 (9.2–26.1) < 0.0001
Influenza virus (INFL) 2.2% (11/499) 0.5% (5/1070) 4.8 (1.6–13.9) 0.0014
Other
Varicella-zoster virus (VZV) 1.8% (9) 0.3% (3) ND ND
HHV6 1.2% (6) 0.4% (4) ND ND
Respiratory syncytial virus (RSV) 0.8% (4) 0.2% (2) ND ND
Parainfluenza virus (PIF) 0.4% (2) 0 ND ND
Metapneumovirus (MPV) 0.2% (1) 0 ND ND
Rotavirus/norovirus 8.4% (42) 0.3% (3) ND ND
Legend: HCT, hematopoietic stem cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic
leukemia; MDS, myelodysplastic syndromes; NHL, non-Hodgkin lymphoma (NHL); HD, Hodgkin lymphoma;
SAA, severe aplastic anemia (SAA); BMF, bone marrow failure; PID, primary immunodeficiencies; NBL, neuro-
blastoma; ES, Ewing sarcoma; MM, multiple myeloma; ND, not done
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Fungal infections
Incidence The 2-year incidence was 25.3% for children and
6.3% for adults (p < 0.001). It was higher both in children for
allo-HCTs (28.3% vs 14.0%; p < 0.0001) and auto-HCTs
(14.7% vs 2.5%; p < 0.0001) (Fig. 1d–f), regardless of the
level of diagnosis: proven (2.7% vs 1.6%; p < 0.0001), prob-
able (5.7% vs 2.1%; p < 0.0001), or possible IFD (16.9% vs
2.3%; p < 0.0001). At 2 years after HCT, incidences of
proven/probable IFD were 8.4% and 3.7% (p < 0.0001) for
children and adults, respectively (Fig. 1g–i). The frequency
was higher both in pediatric patients with ALL (29.4% vs
11.3%; OR = 3.2, p < 0.0001) and AML/MDS (41.2% vs
13.2%; OR = 4.6, p < 0.0001), when compared to adults
(Table 2). Additionally, two cases of PjP infections were di-
agnosed (one pediatric, one adult).
Identification of fungal species Total number of identified
proven fungal infections was 74 (31 in children and 43 in
adults), including 31 (42%) aspergilloses (A. spp. 6 vs 14;
A. fumigatus 5 vs 2; A. flavus 2 vs 2), 34 (46%) candidiases
(C. albicans 9 vs 8; C. glabrata 3 vs 4; C. krusei 1 vs 1;
C. paraps i los i s 1 vs 0 ; C. dub l in ins i s 0 vs 1 ;
C. guillerimondi 0 vs 1; C. kefyr 0 vs 1), 5 (6.8%)
mucormycoses (Mucor spp. 1 vs 3; Rhizopus spp. 1 vs 0),
and 4 (5.2%) other species (Fusarium spp. 2 vs 1;
Cryptococcus spp. 0 vs 1).
TimingMedian time from day of HCT to IFD was 0.9 months
(range 0–19) in children and 0.7 months (range 0–20) in
adults. Median time of therapy of IFD was 24 days (range
1–590; quartiles 12–47) in children and 10 days (range 1–
406; quartiles 9–26) in adults (p < 0.0001).
Risk factors In multivariate analysis, the risk of proven/
probable IFD was higher after allo-HCT than auto-HCT
(HR = 5.4; p < 0.001). In allo-HCT patients, the risk was
higher in children than in adults (HR = 3.9; p < 0.001), in
acute leukemia (HR = 3.8; p < 0.001), MUD vs MSD-HCT
(HR = 1.5; p = 0.013), MMUD vs MSD-HCT (HR = 2.5;
p < 0.001), late (> 21 days) hematological recovery (HR =
3.3; p < 0.001), acute GVHD before infection (HR = 1.5;
p = 0.021), and chronic GVHD before infection (HR = 2.2;
p < 0.001). In auto-HCT patients, the risk was higher in chil-
dren than in adults (HR = 1.8; p = 0.025). Patients with MM
were at lower risk of IFD in comparison to all other patients
(HR = 0.6; p = 0.005) (Table 5).
Outcome Overall outcome of IFD was positive in 88.0% of
infections in children and in 74.9% in adults (OR = 2.1;
Table 3 Distribution and multidrug resistance (MDR) phenotypes of isolated Gram-negative species. The total number of MDR strains contains all
types of resistance, including coexistence of mechanisms
Pathogen Children Adults
Total MDR ESBL AmpC Other Total MDR ESBL AmpC Other
Total 233 158 (67.8%) 153 (65.7%) 5 (2.1%) 4 843 404 (47.9%) 378 (44.8%) 70 (8.3%) 41 (4.8%)
Escherichia coli 58 44 (75.9%) 44 (75.9%) – – 242 75 (31.0%) 75 (31.0%) 7 (2.9%) –
Klebsiella pneumoniae 38 32 (84.2%) 29 (76.3%) – – 274 181 (66.1%) 181 (66.1%) 40 (14.6%) 14 (5.1%)
Enterobacter cloacae 56 52 (92.9%) 52 (92.9%) 3 (5.4%) – 115 79 (68.7%) 70 (60.9%) 21 (18.3%) 10 (8.7%)
Pseudomonas aeruginosa 22 1 (4.5%) – – – 74 36 (48.6%) 22 (29.7%) 2 (2.7%) 14 (18.9%)
Klebsiella oxytoca 13 12 (92.3%) 12 (92.3%) 1 (7.7%) – 17 7 (41.2%) 7 (41.2%) – –
Citrobacter freundii 8 4 (50.0%) 3 (37.5%) 1 (12.5%) – 7 5 (71.4%) 5 (71.4%) – –
Acinetobacter junii 1 – – – – 19 4 (21.1%) 4 (21.1%) – –
Proteus mirabilis 2 2 (100%) 2 (100%) – – 19 4 (21.1%) 4 (21.1%) – –
Stenotrophomonas maltophilia* 11 – – – – 29 – – – –
Salmonella enteritidis – – – – – 6 – – – –
Enterobacter faecium 2 – – – – 13 – – – –
Enterobacter aerogenes 8 8 (100%) 8 (100%0 – – 3 2 (66.7%) 2 (66.7%) – –
Klebsiella spp. 3 1 (33.3%) 1 (33.3%) – – – – – – –
Morganella morganii 1 1 (100%) 1 (100%) – – 7 3 (42.9%) 2 (28.6%) – 1 (14.3%)
Enterobacter spp. 2 – – – – 5 1 (20.0%) 1 (20.0%) – –
Serratia spp. – – – – – 10 7 (70.0%) 5 (50.0%) – 2 (20.0%)
Other species 6 – – – – – – – – –
* Stenotrophomonas maltophilia is inherently resistant to most antibiotics except for cotrimoxazole (trimethoprim-sulfamethoxazole) and ticarcillin-
clavulanate
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95%CI = 1.4–3.1; p < 0.0001). The outcome of IFDwas better
in children than adults both after allo- and auto-HCT, regard-
less of the level of IFD diagnosis: proven (88.6% vs 79.6%),
probable (80.8% vs 66.2%), or possible (91.4% vs 78.6%)
(Fig. 2d–j).
Viral infections
Incidence The 2-year incidence of viral infections was 56.3%
for children and 29.3% for adults (p < 0.0001) after allo-HCT,
and 6.6% vs 0.8% (p < 0.0001) after auto-HCT. The frequency
was higher for CMV (28.9% vs 24.7%; OR = 1.7; p < 0.05),
BKV (21.0% vs 5.9%; OR = 5.2; p < 0.0001), EBV (19.4% vs
1.9%; OR = 15.7; p < 0.0001), ADV (7.4% vs 2.9%; OR =
3.5; p < 0.0001), and influenza (2.2% vs 0.5%; OR = 4.8;
p = 0.0038) (Table 2, Fig. 1j–l).
Viral infections after auto-HCT in children developed in 10
patients including 2 (1.3%) CMV, 1 (0.6%) influenza, 1
(0.6%) BKV, 1 (0.6%) ADV, and 5 (3.3%) rotavirus. Viral
infections after auto-HCT in adults developed in 15 patients
including 4 (0.18%) CMV, 5 (0.23%) influenza, 3 (0.14%)
VZV, 2 (0.09%) HHV6, and 1 (0.04%) ADV.
Timing Median time from day of HCT to viral infection was
1.4 months (range 0–19) in children and 1.6 months (range 0–
21) in adults. Median time of therapy of viral infection was
13 days (range 0–168; quartiles 6–24) in children and 12 days
(range 0–401; quartiles 1–28) in adults.
Risk factors In multivariate analysis, the risk of infections was
higher after allo-HCT (HR = 6.1; p < 0.001). In allo-HCT pa-
tients, the risk was higher in children (HR = 1.3; p = 0.010), in
acute leukemia (HR = 1.7; p < 0.001), MUD vs MSD-HCT
(HR = 2.0; p < 0.001), MMUD vs MSD-HCT (HR = 3.3;
p < 0.001), MAC vs RIC (HR = 1.8; p = 0.050), acute
GVHD before infection (HR = 1.5; p < 0.001), and chronic
GVHD before infection (HR = 2.7; p = 0.014). Among auto-
HCT patients, diagnosis ofMMbrought the lower risk of viral
infections (HR = 0.5; p < 0.001) (Table 5).
Outcome Overall outcome of viral infections was positive in
98.6% of infections in children and in 92.3% in adults (OR =
3.3; 95%CI = 1.2–8.7; p = 0.0096). The outcome of viral in-
fections varied between children vs adults: CMV (97.4% vs
94.1%; p = 0.1), BKV (99.0% vs 93.9%; p = 0.075), EBV
(100% vs 81.3%; p < 0.001), ADV (100% vs 96.3%; p =
0.3), and influenza (100% vs 70%; p = 0.5) (Fig. 1k–o).
Deaths from infections
Frequencies Overall, 237 patients died from infection, includ-
ing 7.8% (31/395) children and 18.4% (206/1120) adults
Table 4 Distribution and multidrug resistance (MDR) phenotypes of isolated Gram-positive species. The total number of MDR strains contains all
types of resistance, including coexistence of mechanisms
Pathogen Children Adults
Total MDR MRS VRE Other Total MDR MRS VRE Other
Total 287 125 (43.6%) 56 (19.5%) 49 (17.1%) 34 (11.8%) 461 185 (40.1%) 111 (24.1%) 59 (12.8%) 15 (3.3%)
Clostridium difficile 81 – – – – 92 – – – –
Staphylococcus epidermidis 51 36 (70.6%) 36 (70.6%) – – 129 74 (57.4%) 74 (57.4%) – –
Staphylococcus aureus 16 5 5 – – 20 15 (75.0%) 15 (75.0%) – –
Staphylococcus hominis 9 – – – – 25 4 (16.0%) 4 (16.0%) – –
Enterococcus faecium 86 69 (80.2%) – 49 (57.0%) 34 (39.5%) 53 41 (77.4%) – 26 (47.2%) 15 (28.3%)
Staphylococcus
haemolyticus
18 5 (27.8%) 5 (27.8%) – – 33 10 (30.3%) 10 (30.3%) – –
Enterococcus faecalis 4 – – – – 67 33 (49.3%) – 33 (49.3%) –
Staphylococcus spp. 2 – – – – 19 8 (42.1%) 8 (42.1%) – –
Streptococcus mitis 1 – – – – 6 – – – –
Streptococcus spp. 3 – – – – – – – – –
Staphylococcus warneri 2 – – – – – – – – –
Corynebacterium spp. 1 – – – – 7 – – – –
Streptococcus pyogenes 2 – – – – – – – – –
Streptococcus pneumoniae 3 – – – – 2 – – – –
Streptococcus oralis 2 – – – – 3 – – – –
Micrococcus spp. – – – – – 5 – – – –
Other species 6 – – – – – – – – –
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(OR = 0.4, 95%CI = 0.3–0.6; p < 0.0001). The distribution of
deaths was different in children (35.5% bacterial, 48.4% fun-
gal, 16.1% viral) than in adults (61.7% bacterial, 24.7% fun-
gal, 13.6% viral).
Risk factors for death from infectious complications In allo-
HCT patients, in multivariate analysis, adults (HR = 3.3;
p < 0.001), recipients of MMUD-HCT (HR = 3.8; p < 0.001),
patients with acute leukemia (HR = 1.5; p = 0.023), chronic
GVHD before infection (HR = 3.6; p = 0.014), CMVreactiva-
tion (HR = 1.4; p = 0.038), and in patients with duration of
infection treatment > 21 days (HR = 1.4; p = 0.038) were as-
sociated with increased risk of IRM (Table 6). In separate
analysis of patients with bacterial infections, the risk was
higher in Gram-negative in comparison to Gram-positive in-
fections (HR = 1.6; 95%CI = 1.1–2.1; p = 0.031).
Among auto-HCT patients, no child died of infection.
Among adults, the risk of death was higher if duration of
treatment of infection was > 21 days (HR = 1.7; p < 0.001)
(Table 6). In patients with MM, the risk was lower (HR =
0.4; p < 0.001). In separate analysis of patients with bacterial
infections, there was a trend towards higher IRM in Gram-
negative vs Gram-positive infections (HR = 1.8; 95%CI =
0.9–2.7; p = 0.086).
Discussion
In this study for the first time ever, simultaneous analysis and
comparison of epidemiology and outcome of bacterial, fungal,
and viral infections in a large cohorts of children and adults
after HCT in a multicenter cross-sectional nationwide study
were performed. Both groups largely differed in terms of dis-
tribution of primary diseases and their treatment, types of pre-
parative regimens, and types of transplantation. Although both
pediatric and adult transplant centers used generally very
Table 5 Multivariate analysis of
risk factors for infection Risk factor Bacterial infection Fungal infection Viral infection
HR (95%CI) p HR (95%CI) p HR (95%CI) p
Allo vs auto 2.9 (2.3–3.6) < 0.001 5.8 (4.6–6.9) 0.021 16 (12–20) < 0.001
Allo-HCT
Children vs adults 2.1 (1.8–2.4) < 0.001 3.9 (3.3–4.5) < 0.001 1.3 (1.05–1.5) 0.010
Sex male vs female 1.1 (0.9–1.3) 0.065 0.9 (0.8–1.1) 0.614 0.9 (0.8–1.1) 0.180
Acute leukemia vs other 1.6 (1.4–1.8) < 0.001 3.8 (3.1–4.5) < 0.001 1.7 (1.4–2.1) < 0.001
NHL/HD vs other 1.2 (0.8–1.6) 0.521 1.3 (0.8–1.8) 0.358 1.4 (0.7–2.0) 0.642
Haplo vs other 1.4 (0.8–1.9) 0.162 1.3 (0.7–2.0) 0.315 0.8 (0.3–1.3) 0.520
MUD vs MSD 1.6 (1.2–2.1) < 0.001 1.5 (1.1–1.8) 0.013 2.0 (1.3–2.7) < 0.001
MMUD vs MSD 2.0 (1.4–2.6) < 0.001 2.5 (2.1–2.9) < 0.001 3.3 (2.7–3.9) < 0.001
BM vs PB 1.4 (1.1–1.7) 0.007 1.2 (0.8–1.7) 0.382 0.8 (0.5–1.1) 0.165
MAC vs RIC 1.3 (1.0–1.6) 0.042 1.2 (0.9–1.6) 0.068 1.8 (1.0–2.5) 0.050
TBI vs chemotherapy 1.2 (1.0–1.4) 0.055 1.3 (0.8–1.7) 0.215 1.1 (0.7–1.5) 0.386
ANC recovery: >D21 vs
≤D21 days
3.3 (2.6–4.1) < 0.001 1.2 (0.7–1.9) 0.729 0.8 (0.5–1.1) 0.065
aGVHD before
infection: yes vs no
1.7 (1.4–2.1) < 0.001 1.5 (1.1–2.0) 0.021 1.5 (1.1–2.0) < 0.001
cGVHD before
infection: yes vs no
1.4 (1.1–1.6) 0.014 2.2 (1.8–2.5) < 0.001 2.7 (2.3–3.1) < 0.001
Auto-HCT
Children vs adults 1.7 (1.3–2.1) < 0.001 1.8 (1.1–2.6) 0.025 1.1 (0.6–1.7) 0.872
Sex male vs female 1.2 (0.8–1.5) 0.475 0.8 (0.3–1.5) 0.235 0.8 (0.6–1.1) 0.294
Acute leukemia vs other 1.8 (1.4–2.2) < 0.001 1.7 (1.2–2.1) 0.004 1.5 (1.1–1.2.0) 0.005
NHL/HD vs other 1.0 (0.80–1.2) 0.922 0.9 (0.7–1.2) 0.689 1.1 (0.7–1.4) 0.745
MM vs other 0.7 (0.4–0.9) 0.005 0.6 (0.3–0.8) < 0.001 0.5 (0.2–0.8) < 0.001
ANC recovery: >D21 vs
≤D21 days
2.8 (2.1–3.5) < 0.001 1.0 (0.5–1.5) 0.936 0.9 (0.5–1.3) 0.825
Legend: HCT, hematopoietic stem cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic
leukemia; BM, bone marrow; PB, peripheral blood; TBI, total body irradiation; a/cGVHD, acute/chronic graft
versus host disease; MUD, matched unrelated donor; MSD, matched sibling donor; MMUD, mismatched unre-
lated donor; MAC, myeloablative conditioning; RIC, reduced intensity of conditioning; NHL, non-Hodgkin
lymphoma (NHL); HD, Hodgkin lymphoma; MM, multiple myeloma; ANC, absolute neutrophil count; D, days
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similar strategy of anti-infective management [18], some dif-
ferences between these settings existed, as pediatric centers
used many off-label compounds. In this study, we analyzed
patients over a period of 4 years, when anti-infective
prophylaxis and treatment did not change substantially in both
pediatric and adult centers.
Bacterial infections occurred mainly during neutropenic,
pre-engraftment phase. In adults, Gram-negative bacteria were
more often documented, while in children Gram-positive spe-
cies. The rate of MDR Gram-negative strains was higher in
pediatric than in adult centers, while the rate of Gram-positive
MDR was comparable in these cohorts. Our results indicate
the shift of prevalence from Gram-positive to Gram-negative
bacteria in a population of adult hematology patients and in-
creasing incidence of MDR bacteria, especially Gram-
Fig. 2 Outcome of infections. Bacterial infections a total, b allo-, and c
auto-HCT. Fungal infections d total, e allo-, and f auto-HCT.With respect
to level of IFD diagnosis g total, h children, and i adults. j Candida vs
Aspergillus infections. Viral infections in k children vs adults. l CMV,
BKV, EBV, and ADV infections.m CMV in children vs adults. n EBV in
children vs adults. o ADV in children vs adults
Table 6 Multivariate analysis for
risk factors for death from
infection after HCT
Risk factor HR (95%CI) p
Allo vs auto-HCT 6.3 (5.2–7.6) < 0.001
ALLO-HCT
Adults vs children 3.3 (3.0–3.6) < 0.001
Bacterial infection 1.1 (0.8–1.4) 0.527
Fungal (p/p) infection 1.6 (0.9–2.4) 0.082
Viral infection 1.5 (0.7–2.2) 0.392
CMV reactivation 1.4 (1.0–1.8) 0.038
Sex male vs female 1.1 (0.9–1.3) 0.962
Acute leukemia vs other 1.5 (1.1–1.9) 0.023
NHL/HD vs other 1.0 (0.8–1.2) 0.873
Haplo vs other 1.1 (0.8–1.3) 0.285
MUD/ vs MSD 1.3 (0.8–1.8) 0.259
MMFD vs MSD 3.8 (3.0–4.7) < 0.001
BM vs PB 0.8 (0.3–1.4) 0.337
MAC vs RIC 1.1 (0.5–1.7) 0.872
TBI vs chemotherapy 1.1 (0.8–1.4) 0.498
aGVHD before infection: yes vs no 1.0 (0.5–1.6) 0.849
cGVHD before infection: yes vs no 3.6 (2.2–4.7) < 0.001
ANC recovery: >D21 vs ≤D21 days 1.6 (0.8–2.5) 0.115
First infection: <D30 vs ≥D30 days 1.1 (0.4–1.6) 0.705
Treatment duration of infection: >D21 vs ≤D21 days 1.9 (1.1–2.7) 0.027
Auto-HCT
Adults vs children 2.9 (1.5–4.8) < 0.001
Bacterial infection 1.4 (0.7–2.2) 0.585
Fungal (p/p) infection 1.4 (0.7–2.3) 0.732
Viral infection 1.1 (0.2–1.9) 0.856
Sex male vs female 1.3 (0.8–1.9) 0.439
NHL/HD vs other 1.1 (0.3–1.9) 0.823
MM vs other 0.4 (0.1–0.8) < 0.001
ANC recovery: >D21 vs ≤D21 days 1.3 (0.9–1.8) 0.092
First infection: <D30 vs ≥D30 days 1.1 (0.6–1.7) 0.774
Treatment duration of infection: >D21 vs ≤D21 days 1.7 (1.2–2.5) < 0.001
Legend. HR, hazard ratio; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; AL, acute leuke-
mia; HCT, hematopoietic cell transplantation; BM, bone marrow; PB, peripheral blood; CMV, cytomegalovirus;
TBI, total body irradiation; a/cGVHD, acute/chronic graft versus host disease; MUD, matched unrelated donor;
MSD, matched sibling donor; MMUD, mismatched unrelated donor; MAC, myeloablative conditioning; RIC,
reduced intensity of conditioning; NHL, non-Hodgkin lymphoma (NHL); HD, Hodgkin lymphoma;MM, multi-
ple myeloma; ANC, absolute neutrophil count; D, days
Ann Hematol (2019) 98:2197–2211 2207
negative [26, 27]. It is debatable, if use of quinolones in adults
or oral gentamycin in children have possible negative impact
in the selection of resistant gut microbiome [27]. We con-
firmed that irrespectively to age, transplant performed from
alternative donor and prolonged neutropenia were indepen-
dent risk factors for the development of bacterial infection
[28]. The differences in bacterial epidemiology between chil-
dren and adults resulted in differences in outcome of bacterial
infections in these two cohorts, with a higher risk for death
related to Gram-negative bacteria. High rate in bacterial infec-
tions was found for typical pediatric primary diagnoses like
primary immunodeficiencies, neuroblastoma, and Ewing sar-
coma; and opposite, in adulthood disease multiple myeloma,
the rate was much lower and reached 12.9%.
Fungal infections were much more frequently diagnosed
in children, regardless of the level of diagnosis; however, it
was predominant for possible IFD. It reflects “real-life”
pediatric strategy of reducing invasive diagnostics in chil-
dren. It seems that lower incidence of IFD in adults might
result from general strategy of protective environment in
transplant setting and the prophylactic use of posaconazole
during intensive chemotherapy in AML/MDS, according
to ECIL recommendations [29–31]. Additionally, modified
transplant procedure for pretransplant IFD, such as no-TBI
conditioning, RIC, or use of PB as a stem cell source, could
have possibly decrease the rate of fungal reactivations [1,
32]. Proven IFD were more often diagnosed in children.
This was due mainly because of diagnosis of candidemia,
as children usually have permanent, while adults rather
temporarily central venous catheters. Most of children
were also receiving TPN, while it was rather infrequent
practice in adults. Relatively high rate of candidemia
among proven IFD in children probably contributed to
lower IRM than in case of invasive aspergillosis, as report-
ed recently [33].
The incidence of viral infections was higher in children
than in adults. This observation can be explained by immature
immune system in children, resulting in primary infection or
higher rate of reactivation of latent viruses. CMV and EBV
were two most often diagnosed viruses in children after allo-
HCT. CMV exerts direct and indirect effects in tissues and
often plays a role of driver of another infections, including
IFD, thus contributing to an increased post-transplant risk of
life-threatening complications. With respect to respiratory vi-
ral infections, there is no current strategy of routine monitor-
ing of community-acquired respiratory viruses; thus, no firm
conclusion can be drawn on this topic from our study.
IRM was higher in adults, what has been evidence-proved
for the first time. Additionally, IRM was higher in Gram-
negative infections and in patients with acute leukemia. The
outcome of infections was better in children both after allo-
and auto-HCT. In addition to well-defined factors for mortal-
ity (acute leukemia, MMUD, GVHD, CMV reactivation),
duration of infection > 21 days was associated with an in-
creased risk of death after infection.
The higher infection rate of MDI in children in comparison
to adults can be explained by the following factors: (1) much
higher rate of auto-HCT in adults resulting in overall lower
incidence of infections in adults, especially seen in case of
bacterial complications; (2) higher rate of patients with acute
leukemia in pediatric cohort, with a well-known high inci-
dence of infectious complications in acute leukemia [8, 34];
(3) much higher rate of diagnosis of possible IFD in children
being the consequence of the positive results of imaging only;
(4) higher incidence of viral infections in children, what can
correspond to higher rate of primary infections; and finally, (5)
real-life tendency of pediatricians to perform more detailed
diagnostic procedures. Due to the same factors, the diagnosis
of multiple myeloma was associated with a decreased risk for
infection in multivariate analysis. On the other hand, the inci-
dence of infectious complications in this group of patients was
similar as presented in recent analyses [35–38].
The limitation of the study is its retrospective design; how-
ever, data were collected periodically. Also no routine screen-
ing was performed for viral infections except CMVand EBV.
Thus, in most cases of viral infections, the diagnosis was
bound to clinical symptoms.
In conclusion, the profile of infections and related deaths
largely vary between children and adults. Our study proved
age-dependent determinants of pediatric and adulthood profile
of infectious complications after HCT: children have higher
risk of all types of infections and a better outcome of bacterial
infections, while in fungal and viral infections, the IRM was
comparable between children and adults. Adult age, MMUD
transplants, diagnosis of acute leukemia, chronic GVHD,
CMV reactivation, and infection lasting > 21 days are relative
risk factors for death from infection after HCT. The potential
implication of this comprehensive analysis might be differen-
tial infection control and management strategies for children
and adults.
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